Aggressive Versus Non-aggressive Goal-directed Fluid Resuscitation in Acute Pancreatitis
- Conditions
- Acute Pancreatitis
- Interventions
- Drug: Lactated Ringer Solution
- Registration Number
- NCT04381169
- Lead Sponsor
- Enrique de-Madaria
- Brief Summary
WATERFALL is an investigator-initiated international multicenter open-label randomized clinical trial comparing aggressive versus moderate fluid resuscitation in acute pancreatitis. The main outcome variable will be the proportion of patients with moderate-to-severe AP. Aggressive fluid resuscitation will consist in Lactated Ringer Solution (LR) 20 ml/kg bolus (administered over 2 hours) followed by LR 3 ml/kg/h and moderate a LR bolus 10 ml/kg in case of hypovolemia or no bolus in patients with normal volemia, followed by LR 1.5 ml/kg/h. The patients will be assessed at 3 (±1), 12 (±4), 24 (±4), 48 (±4) and 72 (±4) hours from recruitment, and fluid resuscitation will be adjusted to the patient´s clinical and analytical status according to a protocol. Subgroup analysis will include patients with systemic inflammatory response syndrome (SIRS) at admission, with persistent (\>48h) SIRS and with hypovolemia at admission.
Based on available data (Sternby et al, Ann Surg 2019) we expect a 35% incidence of moderate to severe AP in the moderate arm. Sample sizes of 372 per arm of treatment (744 patients) achieve 80% power to detect a difference of 10% between the treatment arms at a significance level (alpha) of 0.05 using a two-sided z-testNA, assuming a 10% dropout. These results assume that 3 sequential tests are made using the O'Brien-Fleming spending function to determine the test boundaries.
All analyses will be performed on an intention-to-treat basis. The trial could be stop early for efficacy (primary end-point) if the observed two-sided P value is \<0.0002 at the first interim analysis (after 1/3 of patients have been enrolled) or is \<0.012 at second interim analysis (after 2/3 of patients have been enrolled), favoring aggressive fluid resuscitation. At final analysis, the hypothesis that the incidence of moderate-to-severe pancreatitis is similar in the two treatment arms will be rejected if p\<0.046
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 249
- Patients age greater or equal to 18 presenting to one of the collaborating centers
- Diagnosis of acute pancreatitis according to the revised Atlanta classification which requires 2 of the following 3 criteria: A) Typical abdominal pain; B) Increase in serum amylase or lipase levels higher than 3 times the upper limit of normality; and C) Signs of AP in imaging.
- Uncontrolled arterial hypertension (systolic blood pressure >180 and/or diastolic blood pressure 100 mmHg);
- New York Heart Association Class II hear failure (slight limitation of physical activity; fatigue, palpitations or dyspnea with ordinal physical activity) or worse, or ejection fraction<50% in the last echocardiography;
- Decompensated cirrhosis (Child's Class B or C);
- Hyper or hyponatremia (<135 or >145 mEq/l);
- Hyperkalemia (>5 mEq/l);
- Hypercalcemia (albumin or protein-corrected calcium>10.5 mg/dl);
- Chronic kidney failure (basal glomerular filtration rate <60 mL/min/1.73m2);
- Clinical signs or symptoms of volume overload or heart failure at recruitment (dyspnea, peripheral edema, pulmonary rales, or evident increased jugular ingurgitation at 45º);
- Shock or respiratory failure according to the revised Atlanta classification at recruitment (non-fluid responding systolic blood pressure< 90 mmHg, PaO2/FIO2≤300 mmHg);
- Time from pain onset to arrival to emergency room >24h;
- Time from confirmation of pancreatitis to randomization >8h;
- Severe comorbidity associated with an estimated life expectancy <1 year;
- Confirmed chronic pancreatitis (in case of recurrent alcoholic pancreatitis a recent (<6 months) CT scan/MRI or endoscopic ultrasound is needed to rule out chronic pancreatitis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Aggressive fluid resuscitation Lactated Ringer Solution Lactated Ringer Solution 20 ml/kg bolus (administered over 2 hours) followed by an infusion of 3 ml/kg/h. At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation is maintained at least 48h, and then it can be stopped in case of tolerating oral feeding for at least 8 hours Moderate fluid resuscitation Lactated Ringer Solution At recruitment: A) Hypovolemia: Lactated Ringer Solution 10 ml/kg bolus (administered over 2 hours) followed by an infusion of 1.5 ml/kg/h. B) No hypovolemia: infusion of lactated Ringer Solution of 1.5 ml/kg/h (no bolus). At 12(±4) hours: A) Hypovolemia: same bolus and infusion B) No hypovolemia: infusion of lactated Ringer Solution 1.5 ml/kg/h C) Fluid overload: infusion rate of lactated Ringer Solution will be decreased or stopped Similar adjustments are repeated at 24(±4), 48(±4) and 72(±4) hours Fluid resuscitation can be stopped before the first 48h in case of tolerating oral feeding for at least 8 hours
- Primary Outcome Measures
Name Time Method Moderate-to-severe acute pancreatitis From admission to discharge, up to 24 weeks Moderate or severe category of the Revised Atlanta Classification (Banks et al, Gut 2013)
- Secondary Outcome Measures
Name Time Method PAN-PROMISE scale At 12, 24, 48 and 72 hours Score on an acute pancreatitis Patient-Reported Outcome Measurement
Shock From admission to discharge, up to 24 weeks Systolic blood pressure \<90 mmHg after fluid resuscitation
Local complications (acute peripancreatic fluid collections/ pancreatic necrosis/peripancreatic necrosis) From admission to discharge, up to 24 weeks As described on the revised Atlanta classification, Banks et al, Gut 2013
C-reactive protein 48 and 72 hours Blood levels of C-reactive protein
Death and/or persistent organ failure and/or infection of pancreatic necrosis From admission to discharge, up to 24 weeks Analyzed as a composite endpoint and each of its components, includes in-hospital mortality, persistent organ failure (according to the revised Atlanta classification, Banks et al, Gut 2013) or infection of pancreatic necrosis
Length of hospital stay From admission to discharge, up to 24 weeks Need for nutritional support From admission to discharge, up to 24 weeks Need for enteral/parenteral feeding
Kidney failure From admission to discharge, up to 24 weeks Creatinine \>1.9 mg/dL
Fluid overload From admission to discharge, up to 24 weeks Fluid overload is defined by the absence of Acute Respiratory Distress Syndrome and at least 2 of the following 3 criteria (based on Sharma et al, Lancet Diabetes Endocrinol 2016, with modifications):
Criteria 1. Hemodynamic-imaging evidence (≥1):
* Non-invasive diagnostic evidence of heart failure (i.e., echocardiographic, cardiac MRI)
* Radiographic evidence of pulmonary congestion
* Invasive cardiac catheterization suggesting evidence of heart failure (i.e., pulmonary capillary wedge pressure \[or left ventricular end-diastolic pressure\] \>18 mm Hg, right arterial pressure \[or central venous pressure\] \>12 mm Hg, or cardiac index \< 2·2 L/min per m2)
Criteria 2. Heart failure symptoms (1):
- Dyspnea
Criteria 3. Heart failure signs (≥1):
* Peripheral edema
* Pulmonary rales or crackles, or crepitation
* Increased jugular venous pressure, hepatojugular reflux, or bothRespiratory failure From admission to discharge, up to 24 weeks PaO2/FIO2\<300
Intensive care unit stay From admission to discharge, up to 24 weeks Need for intensive care unit (ICU) admission, and days admitted in the ICU
Need for invasive treatment From admission to discharge, up to 24 weeks Endoscopic, percutaneous or surgical treatment of acute pancreatitis complications
Systemic inflammatory response syndrome (SIRS) Baseline, 12, 24, 48 and 72 hours SIRS at the different checkpoints. Presence of persistent (\>48h) SIRS
Trial Locations
- Locations (2)
Alicante
🇪🇸Alicante, Spain
Hospital General Universitario de Alicante
🇪🇸Alicante, Spain